Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Total Non-Current Liabilities: 2013-2024

Historic Total Non-Current Liabilities for Ocular Therapeutix (OCUL) over the last 8 years, with Dec 2024 value amounting to $129.3 million.

  • Ocular Therapeutix's Total Non-Current Liabilities rose 11.15% to $137.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $137.7 million, marking a year-over-year increase of 11.15%. This contributed to the annual value of $129.3 million for FY2024, which is 1.22% down from last year.
  • Latest data reveals that Ocular Therapeutix reported Total Non-Current Liabilities of $129.3 million as of FY2024, which was down 1.22% from $130.9 million recorded in FY2023.
  • Over the past 5 years, Ocular Therapeutix's Total Non-Current Liabilities peaked at $130.9 million during FY2023, and registered a low of $87.5 million during FY2020.
  • Its 3-year average for Total Non-Current Liabilities is $122.6 million, with a median of $129.3 million in 2024.
  • Per our database at Business Quant, Ocular Therapeutix's Total Non-Current Liabilities increased by 24.50% in 2020 and then dropped by 1.22% in 2024.
  • Over the past 5 years, Ocular Therapeutix's Total Non-Current Liabilities (Yearly) stood at $87.5 million in 2020, then climbed by 10.57% to $96.7 million in 2021, then climbed by 11.23% to $107.6 million in 2022, then climbed by 21.74% to $130.9 million in 2023, then declined by 1.22% to $129.3 million in 2024.